摘要
目的:分析急性脑梗死患者在静脉溶栓基础上联合应用尤瑞克林的效果及对NIHSS、mRS评分的影响。方法:选取2018年6月-2020年6月本院收治的急性脑梗死患者100例为研究对象,按照随机抽签法将其分为对照组和研究组,每组50例。对照组给予常规治疗联合静脉溶栓治疗,研究组在对照组基础上联合应用尤瑞克林进行治疗。比较两组的治疗效果、治疗前后的NIHSS评分、相关血清指标以及治疗后3个月的mRS评分。结果:研究组总有效率为94.00%,高于对照组的78.00%,差异有统计学意义(P<0.05)。经过治疗,两组NIHSS评分均有下降趋势。治疗2周后,研究组NIHSS评分明显低于对照组(P<0.05)。治疗后3个月,研究组mRS评分明显优于对照组(P<0.05)。经过治疗,两组MCP-1、GFAP水平均有下降趋势,BDNF、NGF水平均有上升趋势。治疗2周后,研究组MCP-1、GFAP水平均低于对照组,BDNF、NGF水平均高于对照组,差异均有统计学意义(P<0.05)。结论:急性脑梗死患者在静脉溶栓基础上联合应用尤瑞克林的效果较好,可有效改善患者的神经功能及预后情况,且对于血清MCP-1、BDNF、GFAP、NGF指标可起到良好的调节作用,应用价值较高。
Objective:To analyze the effect of intravenous thrombolytic therapy combined with Urinary Kallidinogenase and its influence on NIHSS and mRS scores in patients with acute cerebral infarction.Method:A total of 100 patients with acute cerebral infarction admitted to our hospital from June 2018 to June 2020 were selected as the research objects,they were divided into control group and study group according to the random drawing method,50 cases in each group.The control group was given conventional treatment combined with intravenous thrombolytic therapy,and the study group was treated with Urinary Kallidinogenase based on the control group.Treatment effect,NIHSS score before and after treatment,related serum indexes and mRS score 3 months after treatment were compared between the two groups.Result:The total effective rate of the study group was 94.00%,higher than 78.00%of the control group,the difference was statistically significant(P<0.05).After treatment,NIHSS scores in both groups showed a downward trend.After 2 weeks of treatment,NIHSS score of the study group was significantly lower than that of the control group(P<0.05).3 months after treatment,mRS score in the study group was significantly better than that in the control group(P<0.05).After treatment,the levels of MCP-1 and GFAP in both groups showed a downward trend,while the levels of BDNF and NGF showed an upward trend.After 2 weeks of treatment,the levels of MCP-1 and GFAP in the study group were lower than those in the control group,while the levels of BDNF and NGF were higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion:The combination of intravenous thrombolytic therapy with Urinary Kallidinogenase in patients with acute cerebral infarction has a good effect,which can effectively improve the neurological function and prognosis of patients,and has a good regulation effect on serum MCP-1,BDNF,GFAP and NGF indicators,and has a high application value.
作者
江爱民
JIANG Aimin(Chibi General Hospital,Chibi 437300,China)
出处
《中国医学创新》
CAS
2021年第33期17-20,共4页
Medical Innovation of China
关键词
急性脑梗死
静脉溶栓
尤瑞克林
NIHSS评分
mRS评分
Acute cerebral infarction
Intravenous thrombolysis
Urinary Kallidinogenase
NIHSS score
mRS score
